Company overview

Croda International (LSE:CRDA) is a FTSE 100 specialty-chemicals company organised into three segments: Consumer Care, covering beauty actives, home care and fragrances; Life Sciences, spanning crop protection and pharma — including lipid systems used in mRNA vaccines and gene therapies; and Industrial Specialties. Led by long-serving chief executive Steve Foots, it trades around 3,265p for a Market Capitalisation of roughly £4.5bn, near record highs, and yields about 3.4%. Its appeal has long rested on innovation-led, high-margin niches within chemicals.

Latest developments

The recent trajectory has been one of recovery meeting selective retreat. The full-year 2025 results, reported in February 2026, showed organic growth returning and crop protection rebounding strongly as customer destocking ended, though management cautioned the inventory-rebuild tailwind would not repeat. More strikingly, Croda placed a lipids Facility on standby and took a sizeable exceptional charge, as drug-development timelines normalised after the Pandemic and slowed clinical Demand — a check on the mRNA-lipids growth story. A transformation programme targeting around £100m of annualised benefits by 2028 continued to deliver.

The July 2026 half-year results were the clearer inflection. Organic Sales growth accelerated from about 1% in the first quarter to 9% in the second, adjusted operating profit rose and margins expanded, and the shares jumped on the beat. Consumer Care led the way, with beauty actives and ceramides growing strongly and wins among major Asian beauty brands, while new facilities in China and India came on stream. The Interim Dividend was held.

Financial performance

The half-year numbers were solid. Revenue rose to about £880m, adjusted operating profit climbed to £155.8m at a Margin of 17.7%, and pre-tax profit and Earnings Per Share grew strongly, helped by lower exceptional charges than the prior year. Net Debt sat around £578m at 1.4 times EBITDA, with free Cash Flow improving. The interim dividend was maintained. Segmentally, Consumer Care grew strongly, Life Sciences was broadly flat as pharma solutions lagged on project timing, and Industrial Specialties declined — a pattern of concentrated, not broad-based, growth.

Industry outlook

The specialty-chemicals sector is emerging from a multi-year destocking cycle, and Croda’s own crop-protection rebound exemplifies the pattern — though the company stresses that was a one-off inventory unwind rather than durable demand growth. Pharma-lipid demand has proven lumpy, with drug-development timelines normalising post-pandemic prompting Croda to idle capacity rather than expand it. Consumer beauty, particularly premium actives in Asia, is the brighter, more structural growth theme underpinning the recovery.

The lipids question

Croda’s pharma-lipids Business is worth dwelling on because it was, not long ago, the centre of the bull case. Lipid systems are the delivery vehicles that carry the active ingredients of mRNA vaccines and gene therapies into the body, and during the pandemic Croda’s exposure here was seen as a transformational growth engine. The subsequent normalisation of drug-development timelines has been a reality check: demand has proven lumpy and project-driven, prompting the company to idle capacity and take a charge rather than expand. Management still argues the long-term demand for lipids will grow, and a recovery in pharma solutions is a stated hope for the second half — but the episode is a reminder that even the most exciting structural theme can disappoint in the near term.

Bull case

The bull case is a genuine inflection with self-help behind it. Second-quarter organic growth accelerated to 9% with margin expansion, consumer care momentum is broad and premium — signalling pricing power and innovation — and a credible transformation programme targets around £100m of benefits and a margin above 20% by 2028. Continued deleveraging and a maintained dividend round out a stock re-rating toward record highs.

Bear case and risks

The bear case is that the recovery is narrow and the valuation full. Industrial specialties is still shrinking, life sciences is flat, and the pharma-lipids business — once a growth centrepiece — is in retrenchment, with a facility idled and a charge taken. The 2025 crop-protection strength was a destocking tailwind that will not recur, and with the shares near record highs on a mid-20s earnings multiple, expectations are elevated, leaving little room for disappointment if consumer momentum fades or currency moves against the group.

Key catalysts

Catalysts include the third-quarter trading update as a test of whether the second quarter’s acceleration persists, a hoped-for recovery in pharma solutions in the second half, continued delivery of transformation savings toward the 2028 targets, and currency movements, which management has flagged as a swing Factor for reported profit.

Conclusion

Croda International (LSE:CRDA) is genuinely emerging from its downturn, with accelerating growth, expanding margins and a share price back at record highs. But the rebound is consumer-led and uneven, with the industrial arm still contracting and the once-hyped pharma-lipids story in retreat. The self-help programme and beauty momentum give the recovery real substance; the narrowness of it, and a full valuation, are the reasons to temper the enthusiasm. The turn is real — just not yet firing on every cylinder.